Suxia Luo

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Ming Yi, Jing Zhang, Anping Li et al. · Journal of Hematology & Oncology · 2021 · 239 citations · Full text

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei et al. · Cancer Communications · 2021 · 182 citations · Full text

Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study

Ming Yi, Tianye Li, Mengke Niu et al. · Biomarker Research · 2021 · 177 citations · Full text

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma

Ming Yi, Anping Li, Linghui Zhou et al. · Cancer Immunology Immunotherapy · 2021 · 133 citations · Full text